Pharmacokinetics profile of famciclovir sustained release capsules in healthy volunteers
Yun Chen
Abstract
Yun Chen
Abstract
AIM: To investigate the pharmacokinetic profile and relative bioavailability of Famciclovir sustained release capsules in healthy volunteers.METHODS: 12 healthy volunteers were divided into four group with single oral dose test famciclovir sustained release capsules(250,375,750 mg) and conventional Facmciclovir tablets(750 mg)according to an open randomized four way crossover design.A multi-dose test were given to 10 healthy volunteers according to an open randomized two way crossover design.The concentration of penciclovir in plasma after administration were determinded by HPLC.Pharmacokinetic parameters were calculated with 3P97 program.RESULTS: Concentration-time curves of penciclovir fitted to one-compartment mode,Cmax were(0.31±0.06),(0.51±0.09),(1.0±0.16) μg/mL,tmax(4.4±1.8),(4.0±1.4),(4.3±1.8) h,MRT(6.9±1.3),(7.3±1.0),(7.6±0.7) h,AUC0~24(3.3±0.8),(5.2±1.1),(11.3±1.4) μg·mL-1·h respectively for famciclovir sustained release capsules;Cmax were(3.81±0.38) μg/mL,tmax(1.2±0.6) h,MRT(3.3±0.4) h,AUC0-24(13.7±1.5) μg·mL-1·h for conventional tablet.The relative bioavailability was 81.96%±2.54%.The parameters after multi-doses of the sustain released capsules and conventional tablets were as follows: Cmin(0.32±0.13) and(0.16±0.04) μg/mL,Cmax(0.71±0.14) and 1.67±0.44 μg/mL,Cav(0.44±0.09) and(0.56±0.13) μg/mL,DF 90%±26% and 270%±59%,respectively.CONCLUSION: The sustain released capsules have the obvious sustained release characteristic.The two formulation of Famciclovir are of bioequivalence.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
AIM: To investigate the pharmacokinetic profile and relative bioavailability of Famciclovir sustained release capsules in healthy volunteers.METHODS: 12 healthy volunteers were divided into four group with single oral dose test famciclovir sustained release capsules(250,375,750 mg) and conventional Facmciclovir tablets(750 mg)according to an open randomized four way crossover design.A multi-dose test were given to 10 healthy volunteers according to an open randomized two way crossover design.The concentration of penciclovir in plasma after administration were determinded by HPLC.Pharmacokinetic parameters were calculated with 3P97 program.RESULTS: Concentration-time curves of penciclovir fitted to one-compartment mode,Cmax were(0.31±0.06),(0.51±0.09),(1.0±0.16) μg/mL,tmax(4.4±1.8),(4.0±1.4),(4.3±1.8) h,MRT(6.9±1.3),(7.3±1.0),(7.6±0.7) h,AUC0~24(3.3±0.8),(5.2±1.1),(11.3±1.4) μg·mL-1·h respectively for famciclovir sustained release capsules;Cmax were(3.81±0.38) μg/mL,tmax(1.2±0.6) h,MRT(3.3±0.4) h,AUC0-24(13.7±1.5) μg·mL-1·h for conventional tablet.The relative bioavailability was 81.96%±2.54%.The parameters after multi-doses of the sustain released capsules and conventional tablets were as follows: Cmin(0.32±0.13) and(0.16±0.04) μg/mL,Cmax(0.71±0.14) and 1.67±0.44 μg/mL,Cav(0.44±0.09) and(0.56±0.13) μg/mL,DF 90%±26% and 270%±59%,respectively.CONCLUSION: The sustain released capsules have the obvious sustained release characteristic.The two formulation of Famciclovir are of bioequivalence.
Key concepts: Penciclovir, Cmax, Famciclovir, Pharmacokinetics, Bioavailability, Cmin, Bioequivalence, Crossover study